Modified peptides and their use for treating autoimmune diseases
The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.
1. A peptide, or a salt thereof, comprising or consisting of the amino acid sequence of SEQ ID NO: 2
[SEQ ID NO: 2]
IHMVYSKRSGKPRGYAFIEY,
comprising a phosphoserine at position 9, and an oxidized Methionine at position 3.
2. A peptide, or salt thereof, comprising or consisting of the amino acid sequence of SEQ ID NO: 1
[SEQ ID NO: 1]
RIHMVYSKRSGKPRGYAFIEY,
comprising a phosphoserine at position 10, and an oxidized Methionine at position 4.
3. A composition comprising a peptide according to claim 1 or 2 , and a drug having an immunosuppressive or an immunomodulatory effect.
4. A pharmaceutical composition comprising a peptide according to claim 1 or 2 , further comprising a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4 , which is in the form of a lozenge, tablet, gelatin, capsule, drop, pill, liposome, nano particles or in the form of a solution.
6. A method of treating an autoimmune disease, wherein the method comprises the step of administering to a patient in need of such treatment a pharmaceutical composition according to claim 4 , in an amount sufficient to effect said treatment.
7. The method according to claim 6 , wherein said autoimmune disease is chosen among autoimmune pathologies of the family of connective tissue diseases (non-specific systemic organ diseases); and/or organ-specific autoimmune pathologies.
8. The method according to claim 6 , wherein said autoimmune disease is SLE.
9. The method according to claim 6 , wherein the peptide of said pharmaceutical composition is administered at a dosage in an amount in a range of about 100 ng to about 5 mg.
10. The method of claim 7 , wherein the connective tissue diseases is systemic lupus erythematosus (SLE), rheumatoid arthritis, mixed connective tissue disease, Sjögren's syndrome, or chronic juvenile arthritis.
11. The method of claim 7 , wherein the organ-specific autoimmune pathologies is multiple sclerosis, insulin-dependent diabetes, Crohn's disease, or bullous diseases.